Cobalis gets positive Phase III results on PreHistin

Anti-allergy specialist Cobalis announced that data from its Phase III clinical trial show that preseasonal treatment with PreHistin, its flagship anti-allergy medication, clearly reduced allergy symptoms. The study showed that patients using PreHistin had "significant" reduction in perceived symptoms. The results include only patient-reported data; the company expects to announce analysis of data from clinical exams and blood samples within six weeks.

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.